Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: Detected by terminal-deoxynucleotidyl-transferase- mediated dUTP-FITC nick end labelling (TUNEL)

Histopathology

Volumn 31, Issue 6, 1997, Pages 534-539

  Harn, H J ^a   Shen, K L ^a   Yueh, K C ^a   Ho, L I ^b   Yu, J C ^a   Chiu, S C ^a   Lee, W H ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Oestrogen receptor; p53; Progesterone receptor; TUNEL

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CARCINOMA IN SITU; CELL LABELING; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031454511     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.3270906.x     Document Type: Article

References (28)

1. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 1980: 284; 555-556.
2. Kanter PM, Leister KJ, Tomei LD et al. Epidermal growth factor and tumor promoters prevent DNA fragmentation by different mechanisms. Biochem. Biophys. Res. Comm. 1984: 118; 392-399.
3. Duke RC, Cohen JJ. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res. 1986: 5; 289-299.
4. Tomei LD, Kanter P, Wenner CE. Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem. Biophys. Res. Comm. 1988: 155; 324-331.
5. Lane DP. p53: The guardian of the genome. Nature 1992: 358; 15-16.
6. Miyashita T, Harigai M, Hanada M et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994: 54; 3131-3135.
7. Pezzella F, Micklem K, Turley H et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J. Clin. Pathol. 1994: 47; 592-596.
8. Thor AD, Moore DH, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 1992: 84; 845-855.
9. Haldar S, Negrini M, Monne M et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994: 54; 2095-2097.
10. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995: 55; 2487-2489.
11. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992: 119; 493-501.
12. Wijsman JH, Jinker RR, Keijzer R et al. A new method to detect apoptosis in paraffin section: in situ end-labeling of fragmented DNA. J. Histochem. Cytochem. 1993: 41; 7-12.
13. Kasagi N, Gomyo Y, Shirai H, Tsujitani S, Ito H. Apoptotic cell death in human gastric carcinoma: analysis by terminal-deoxynucleotidyl-transterase-mediated dUTP-biotin nick and labeling. Jap. J. Cancer Res. 1994: 85; 939-945.
14. Ansari B, Coates PJ, Greenstein BD et al. In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J. Pathol. 1993: 170; 1-8.
15. Shinohara T, Ohshima K, Murayama H et al. Apoptosis and proliferation in gastric carcinoma: the association with histological type. Histopathology 1996: 29; 123-129.
16. Aihara M, Truong LD, Dunn JK et al. Frequency of apoptotic bodies positively correlates with gleason grade in prostate cancer. Human Pathol. 1994: 25; 797-801.
17. Arai T, Kino I. Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas. J. Pathol. 1995: 176; 37-44.
18. Leoncini L, Vecchio MTD, Megha T et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am. J. Pathol. 1993: 142; 755-763.
19. Gaffney EF. The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994: 25; 269-273.
20. Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling. Int. J. Cancer 1996: 65; 173-177.
21. Shinohara T, Ohshima K, Murayama H et al. Apoptosis and proliferation in gastric carcinoma: the association with histological type. Histopathology 1996: 29; 123-129.
22. Merlo GR, Basolo F, Fiore L, Duboc L et al. p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J. Cell Biol. 1995: 128; 1185-1196.
23. Ginsberg D, Mechta F, Yaniv M et al. Wild-type p53 can down modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 1991: 88; 9979-9983.
24. Gorczyca W, Markiewski M, Kram A et al. Immunohistochemical analysis of bcl-2 ad p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Archiv. 1995: 426; 229-233.
25. Hockenbery DM. Bcl-2 in cancer, development and apoptosis. J. Cell Sci. 1994: 18; 51-55.
26. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994: 124; 1-6.
27. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994: 73; 2013-2026.
28. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domain of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994: 369; 321-323.